SERIES G COMMON STOCK PURCHASE WARRANT NEUROTROPE, INC.Neurotrope, Inc. • December 17th, 2018 • Pharmaceutical preparations
THIS SERIES G COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June [ ], 2019 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June [ ], 20241 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Neurotrope, Inc., a Nevada corporation (the “Company”), up to ________________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 17th, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2018, between Neurotrope, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
GP NURMENKARI INC. NORWALK, CT 06854 TEL: 212-447-5550 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 17th, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which GP Nurmenkari Inc., a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as the “Placement Agent”), shall be engaged by Neurotrope Inc., a publicly traded Nevada corporation (hereinafter referred to as the “Company”), to act as Placement Agent in connection with the registered direct offering (the “Offering”) of the securities of the Company referred to below (the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”). The Closing (as defined below) of the Offering will be conditioned upon certain conditions described herein.
FORM OF ADVISORY CONSULTING AGREEMENTForm of Advisory Consulting Agreement • December 17th, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
ADVISORY CONSULTING AGREEMENT (the “Agreement”) dated as of December 12, 2018 (the “Agreement”) by and between [ ], a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (the “CONSULTANT”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
